When is a biopsy considered for vulval symptoms?
A vulval biopsy is sometimes suggested when symptoms or skin changes can’t be confidently explained, don’t respond to treatment, or raise specific concerns. Typical triggers include persistent fissures or ulcers, white plaques or thickened areas, areas that bleed easily, changing moles or patches, and unexplained post-menopausal bleeding from the vulva. Many people with genitourinary syndrome of menopause (GSM) won’t need a biopsy; careful history and examination are enough. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
When is a biopsy considered for vulval symptoms? Most vulval symptoms in peri- and post-menopause are explained by genitourinary syndrome of menopause (GSM): thinner mucosa, reduced lubrication, higher pH and fewer lactobacilli lead to dryness, burning and micro-tears. With a typical history and examination, you can usually start step-wise care (moisturisers, suitable lubricant, and—when needed—local oestrogen or DHEA) without tests. A biopsy is considered when skin features are atypical, persistent, or raise specific concerns that can’t be clarified otherwise.
Common situations where clinicians consider biopsy include: (1) Persistent fissures, ulcers or raw areas that fail to heal despite good dryness care and infection being excluded; (2) White patches/plaques, architectural change or scarring suggestive of a dermatosis such as lichen sclerosus; (3) Thickened, warty, or pigmented lesions that are changing in size, colour or feel; (4) Areas that bleed easily, look suspicious, or recur in the same spot; (5) Symptoms out of proportion to visible findings (for example, severe pain or itching with minimal exam findings); and (6) Unexplained post-menopausal bleeding apparently from the vulva (distinct from bleeding that originates in the vagina or uterus).
Why biopsy can be helpful. A small sample examined under the microscope can distinguish between inflammatory skin diseases (e.g., lichen sclerosus or lichen planus), chronic dermatitis, premalignant conditions, infections that mimic dermatitis, and rare but important neoplasia. Getting the diagnosis right avoids months of ineffective or irritating treatments and supports the safest plan, including when potent topical steroids, calcineurin inhibitors, surveillance, or referral are appropriate.
What a biopsy involves. After local anaesthetic, a tiny punch sample is taken from the most representative area (avoiding the most traumatised edge where possible). Stitches are sometimes placed. You’ll receive aftercare advice (salt-water bathing, bland emollient as a barrier, avoiding friction while healing). Discomfort is usually short-lived, but discuss pain relief and any blood-thinning medicines in advance.
What doesn’t usually need biopsy. Typical GSM—dryness, stinging with urine on delicate skin, micro-tears at the entrance after friction, little discharge and no odour change—rarely requires biopsy. Similarly, classic thrush (intense itching, thick white discharge) or bacterial vaginosis (fishy odour, thin grey discharge) are confirmed with swabs rather than biopsy. However, if treatments don’t work as expected, clinicians may revisit the diagnosis and consider a targeted sample.
How this fits into a step-wise pathway. Start with foundations: gentle vulval care (lukewarm water; bland emollient as a soap substitute externally; avoid fragranced washes and wipes), a scheduled vaginal moisturiser several times per week (many prefer hyaluronic-acid formulations), and a suitable personal lubricant for intimacy or examinations (water-based, silicone-based or oil-based—mind latex compatibility). If symptoms persist or skin looks atypical, examination plus selective tests (pH, swabs, urine) guide next steps, and biopsy is added when needed. For how we triage concerns and deliver care, see common clinical concerns and browse our treatment FAQs.
Balancing reassurance and vigilance. Many biopsy results confirm inflammatory or irritant conditions that can be managed effectively with targeted care alongside GSM treatment. Still, new lumps, ulcers, bleeding, or rapidly changing patches deserve prompt review. Early assessment and, where appropriate, biopsy shorten time to the right treatment and peace of mind.
Clinical Context
Who may need biopsy sooner? People with white plaques, scarring or architectural change suspicious for lichen sclerosus; ulcers or non-healing fissures; new lumps or pigmented lesions; or bleeding from a visible vulval area. Those with severe or persistent symptoms despite optimised moisturisers, lubricants and (where appropriate) local oestrogen/DHEA also merit review. Post-menopausal bleeding always needs assessment. If penetration is intolerable despite good lubrication, consider co-existing vestibulodynia or pelvic floor over-activity and seek specialist input.
Who may not need biopsy? People with classic GSM patterns that respond to step-wise care. If swabs confirm thrush or BV and symptoms settle with targeted treatment, biopsy is unnecessary. For uncertain cases, shared decision-making weighs the small procedural risks (brief pain, bleeding, infection, scarring) against the value of diagnostic clarity.
Evidence-Based Approaches
UK resources outline red flags and when to escalate. The NHS explains symptoms and when to seek help for vaginal dryness, painful sex (dyspareunia), and warning signs for vulval cancer. The NICE suspected cancer guideline (NG12) supports prompt referral when concerning features are present, and the NICE menopause guideline (NG23) sets out step-wise care for GSM, helping distinguish cases that don’t require biopsy from those that do.
For inflammatory dermatoses such as lichen sclerosus—a common reason to consider biopsy—the British Association of Dermatologists provides practical diagnostic and management advice: see their leaflet on lichen sclerosus. Where conservative and local hormonal measures are appropriate, evidence syntheses on local oestrogen for post-menopausal vaginal symptoms are available from the Cochrane Library. Peer-reviewed overviews indexed on PubMed discuss GSM mechanisms and differential diagnosis, reinforcing that biopsy is selective—used when the clinical picture is atypical or unresponsive to treatment.
In practice, a targeted approach works best: begin with guideline-aligned conservative care; use swabs, urine tests and pH checks to clarify infection or GSM; and reserve biopsy for persistent, atypical or suspicious lesions where histology will change management.